complement cascade

(redirected from Complement system)
Also found in: Medical, Wikipedia.

complement cascade

[′käm·plə·mənt kas′kād]
(immunology)
The sequential activation of complement proteins resulting in lysis of a target cell.
References in periodicals archive ?
When naturally occurring complement inhibitors are absent or do not function normally, the complement system becomes chronically uncontrolled, causing ongoing inflammation and blood clots in vital organs1,9 In patients with aHUS, uncontrolled complement activation results in an ongoing risk of sudden and catastrophic life-threatening complications.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has closed on a $10 million tranche of a Series B financing, based on substantial progress with the company's product pipeline including advancing the lead product candidate, TT30, toward clinical development.
Taligen has more than 50 issued or pending worldwide patents related to therapeutics that target the complement system.
Novel Biologics Demonstrate Targeting of Complement System to Treat Genetic Disease, Ocular Disease and Organ Transplant
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases.
It is believed that this approach may prevent the complement system, which is a part of the immune system, from mistakenly destroying a person's red blood cells, and potentially halt the CAgD disease process.
The complement system is the major effector of the humoral arm of the immune system.
Chronic uncontrolled activation of the complement system, a part of the immune system, plays a major role in the debilitating symptoms and potentially life-threatening complications for patients with gMG who are anti-AChR antibody-positive.
IONIS-FB-LRx is a ligand conjugated antisense drug for the treatment of diseases stemming from the complement system, which is a part of the immune system that focuses on innate immunity.
Moreover, the complement system is a powerful immune effector that can affect liver function and process of liver cirrhosis.
C3 is a key factor in the complement system and its synthesis is enhanced with inflammation.
The complement system is a pivotal created of the immune system in keeping the steward from infection via many pathogenic agents [10].
Full browser ?